Breast reconstruction with Alloderm Ready to Use: A meta-analysis of nine observational cohorts.

CONCLUSION: Four HADM products, AlloDerm-RTU, FD AlloDerm, AlloMax, and DermACELL, showed similar risks of complications. However since most of the included studies had a low level of evidence, further random trials with large numbers of patients are needed. PMID: 29631098 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29631098?dopt=Abstract

Source: Breast - April 6, 2018 Category: Cancer & Oncology Authors: Wu LH, Zhang MX, Chen CY, Fang QQ, Wang XF, Tan WQ Tags: Breast Source Type: research

More News: Cellulitis | Databases & Libraries | Dermatology | Study